Results 81 to 90 of about 847 (163)

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Expert consensus on gepants for acute and preventive treatment of migraine in Thailand

The Journal of Headache and Pain
Introduction Gepants, a calcitonin gene-related peptide (CGRP) receptor antagonist, is a class of migraine therapeutic options with extensive evidence supporting a favorable efficacy and safety profile. However, as a novel class of medication in Thailand,
Prakit Anukoolwittaya, Wanakorn Rattanawong, Kiratikorn Vongvaivanich, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Thaninjitra Poonpedpun, Pannathat Soontrapa, Kanokrat Suwanlaong, Kannikar Kongbunkiat, Surasak Komonchan, Petcharat Dusitanond, Chutithep Teekaput, Nopdanai Sirimaharaj, Nadolporn Yuvasilp, Surat Tanprawate   +14 more
doaj   +1 more source

Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment

The Journal of Headache and Pain
Background Calcitonin gene related peptide (CGRP) pathway targeting therapies have proven efficacy, safety and tolerability. However, CGRP is also involved in immune responses, and reports of an increased risk of infection have emerged.
Marcin Straburzyński, Daria Kopyt, Karol Marschollek, Bartłomiej Błaszczyk, Ewa Kuca-Warnawin, Weronika Kurowska, Błażej Misiak, Kuan-Po Peng, Marta Waliszewska-Prosół, Arne May   +9 more
doaj   +1 more source

Comparison of gepant effects at therapeutic plasma concentrations: connecting pharmacodynamics and pharmacokinetics

The Journal of Headache and Pain
Background Orally administered second-generation gepants are effective for the treatment of migraine. The intranasal administration of the third-generation gepant zavegepant might have additional benefits including a rapid onset of action, but it is not ...
Deirdre M. Boucherie, Ruben Dammers, Arnaud Vincent, A. H. Jan Danser, Antoinette MaassenVanDenBrink   +4 more
doaj   +1 more source

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of migraine, but its efficacy and safety in people who have been failed by conventional oral preventive migraine treatments
Trugman, Joel M, Nežádal, Tomáš, Forero, Giovanna, Pozo-Rosich, Patricia, De Abreu Ferreira, Rosa, Sacco, Sara, Tassorelli, Cristina, Lanteri-Minet, Michel, Guo, Hua, Nagy, Krisztián   +9 more
core   +1 more source

Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine

Drug Design, Development and Therapy
Mengyi Li, Siyong Huang, Jiabao Li, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Li M, Huang S, Li J, Hu X, Chen J
doaj  

Onabotulinum Toxin A (BoNTA) in the Treatment of Chronic and High-Frequency Episodic Migraine: A Real-World Study. [PDF]

Pharmaceuticals (Basel)
Jiménez-Jiménez FJ, Cárcamo-Fonfría A, Espada-Rubio S, Alonso-Navarro H, San Andrés-Hotema A, Calleja M, Aragón-Díaz N, Ramas-Henrich A, Arroyo-Solera M, Martín-Gómez MÁ, Salgado-Cámara P, Alonso-Zazo FJ, Serna-Romero O, García-Martín E, Agúndez JAG.   +14 more
europepmc   +1 more source

Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Akram Nizamani S, Memon R, Iguh C, Ali R, Omomhenle OD, Oyedeji NO, Zafar S, Nwawueze A, Amjad H, Samuel PS, Gul D.   +10 more
europepmc   +1 more source

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability

: AimTo assess whether the timing of atogepant administration influences its tolerability and effectiveness over 12 weeks in patients with episodic and chronic migraine in a real-world setting.MethodsThis is a post-hoc analysis of the STAR study, a ...
Calabresi, Paolo, Merlo, Paola, Albanese, Maria, Sacco, Simona, Castro, Flavia Lo, Iannone, Luigi Francesco, Guerzoni, Simona, Rufa, Alessandra, Lanni, Claudia, Ferrandi, Delfina, Geppetti, Pierangelo, Vernieri, Fabrizio, Sebastianelli, Gabriele, Battistini, Stefania, Altieri, Marta, Cesaris, Francesco De, Doretti, Alberto, Rainero, Innocenzo, Coppola, Gianluca, Montisano, Danilo Antonio, Munafò, Antonio, Fofi, Luisa, Romozzi, Marina, Marcosano, Marilena, Grazzi, Licia, Corrado, Michele, Boccalini, Alberto, on behalf of the Italian Headache Registry (RICe) Study Group, Giuliani, Giada, Santis, Federico De, Vigani, Giulia, Pistoia, Francesca, Valente, Maria Rosaria, Altamura, Claudia, Ornello, Raffaele, Vaghi, Gloria, Russo, Antonio, Avino, Gianluca, Prudenzano, Maria Pia, Trimboli, Michele, Volta, Giorgio Dalla   +40 more
core   +1 more source

Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents. [PDF]

Curr Pain Headache Rep
Shin L, Moon R, Gelfand A.
europepmc   +1 more source